Peri-Pregnancy Cannabis Use and Autism Spectrum Disorder in the Offspring: Findings from the Study to Explore Early Development

Autor/inn/en	DiGuiseppi, Carolyn; Crume, Tessa; Van Dyke, Julia; Sabourin, Katherine R.; Soke, Gnakub N.; Croen, Lisa A.; Daniels, Julie L.; Lee, Li-Ching; Schieve, Laura A.; Windham, Gayle C.; Friedman, Sandra; Robinson Rosenberg, Cordelia
Titel	Peri-Pregnancy Cannabis Use and Autism Spectrum Disorder in the Offspring: Findings from the Study to Explore Early Development
Quelle	In: Journal of Autism and Developmental Disorders, 52 (2022) 11, S.5064-5071 (8 Seiten) PDF als Volltext Verfügbarkeit
Zusatzinformation	ORCID (DiGuiseppi, Carolyn)
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0162-3257
DOI	10.1007/s10803-021-05339-4
Schlagwörter	Pregnancy; Prenatal Influences; Marijuana; Drug Use; Mothers; Autism Spectrum Disorders; Children; Child Development; Developmental Delays; Probability; Risk; Models; Cohort Analysis; Epidemiology + Suchen Sie Ihr Suchwort? Schwangerschaft; Pränataler Einfluss; Drug consumption; Substance abuse; Drogenkonsum; Mother; Mutter; Autism; Autismus; Child; Kind; Kinder; Kindesentwicklung; Entwicklungsverzögerung; Wahrscheinlichkeitsrechnung; Wahrscheinlichkeitstheorie; Risiko; Analogiemodell; Kohortenanalyse; Epidemiologie
Abstract	The association of autism spectrum disorder (ASD) with self-reported maternal cannabis use from 3 months pre-conception to delivery ("peri-pregnancy") was assessed in children aged 30-68 months, born 2003 to 2011. Children with ASD (N = 1428) were compared to children with other developmental delays/disorders (DD, N = 1198) and population controls (POP, N = 1628). Peri-pregnancy cannabis use was reported for 5.2% of ASD, 3.2% of DD and 4.4% of POP children. Adjusted odds of peri-pregnancy cannabis use did not differ significantly between ASD cases and DD or POP controls. Results were similar for any use during pregnancy. However, given potential risks suggested by underlying neurobiology and animal models, further studies in more recent cohorts, in which cannabis use and perception may have changed, are needed. (As Provided).
Anmerkungen	Springer. Available from: Springer Nature. One New York Plaza, Suite 4600, New York, NY 10004. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-460-1700; e-mail: customerservice@springernature.com; Web site: https://link.springer.com/
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2024/1/01